Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant PK in renal impairment
NCT03087942Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of fevipiprant in asthma (4 arms), sponsored by Novartis. Primary endpoints: Area Under the Curve from time zero to the last measurable concentration at 68 hours, Area Under the Curve from time zero to infinity at 68 hours and 2 more. Started Jul 2017; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03087942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087942.